Mereo BioPharma Reports Interim Data From ACTIVATE Phase 1b/2 Open Label Study Of Etigilimab Anti-TIGIT Antibody In Combination With Nivolumab In Solid Tumors; Says ‘Etigilimab was well tolerated with a favorable safety profile’

by Yogesh Tanwar | Nov 30, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.